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Eutectic Mixture of Local Anaesthetics (EMLA) is recommended for use off-label as a treatment for premature 
ejaculation (PE). Other topical anaesthetics are available, some of which have been evaluated against oral 
treatments. The purpose of this systematic review was to evaluate the evidence from randomised controlled 
trials (RCTs) for topical anaesthetics in the management of PE. Bibliographic databases including MEDLINE 
were searched to August 2014. The primary outcome was intra-vaginal ejaculatory latency time (IELT). 
Methodological quality of RCTs was assessed. IELT and other outcomes were pooled across RCTs in a meta-
analysis. Between-trial heterogeneity was assessed. Nine RCTs were included. Seven were of unclear 
methodological quality. Pooled evidence (two RCTs, 43 participants) suggests that EMLA is significantly more 
effective than placebo at increasing IELT (P < 0.00001). Individual RCT evidence also suggests that Topical 
Eutectic-like Mixture for Premature Ejaculation (TEMPE) spray and lidocaine gel are both significantly more 
effective than placebo (P = 0.003; P < 0.00001); and lidocaine gel is significantly more effective than sildenafil 
or paroxetine (P = 0.01; P = 0.0001). TEMPE spray is associated with significantly more adverse events than 
placebo (P = 0.003). More systemic adverse events are reported with tramadol, sildenafil and paroxetine than 
with lidocaine gel. Diverse methods of assessing sexual satisfaction and ejaculatory control with topical 
anaesthetics are reported and evidence is conflicting. Topical anaesthetics appear more effective than placebo, 
paroxetine and sildenafil at increasing IELT in men with PE. However, the methodological quality of the 
existing RCT evidence base is uncertain.  
Topical anaesthetics were compared with placebo and oral agents for the treatment of premature ejaculation in a 
systematic review and meta-analysis.  Topical anaesthetics are significantly more effective than placebo, 
sildenafil or paroxetine at increasing intra-vaginal ejaculatory latency time.  Topical Eutectic-like Mixture for 
Premature Ejaculation spray is associated with erectile dysfunction, numbness and burning.  More systemic 
adverse events are reported with tramadol, sildenafil and paroxetine than with lidocaine gel. 
Introduction 
Premature ejaculation (PE) is commonly defined by a short ejaculatory latency, a perceived lack of 
ejaculatory control; both related to self-efficacy; and distress and interpersonal difficulty.1 PE can be either 
lifelong (primary), present since first sexual experiences, or acquired (secondary), beginning later.2 A range of 
definitions for PE exist, having been drafted by various professional organisations.3,4 The recently updated 
,QWHUQDWLRQDO6RFLHW\RI6H[XDO0HGLFLQH¶V*XLGHOLQHVIRUWKH'LDJQRVLVDQG7UHDWPHQWRI3UHPDWXUH
Ejaculation (PE) propose that PE is a male sexual dysfunction characterised by ejaculation within approximately 
1 min of vaginal penetration (lifelong PE) or a reduction in latency time to d 3 min (secondary PE), the inability 
to delay ejaculation, and negative personal consequences.5 
The treatment of PE should attempt to alleviate concern about the condition as well as increase sexual 
satisfaction for the patient and the partner.6 Available treatment pathways for the condition are varied and 
treatments may include both behavioural and/or pharmacological interventions. The use of local anaesthetics to 
delay ejaculation reduces the sensitivity of the glans penis thereby delaying ejaculatory latency, but without 
adversely affecting the sensation of ejaculation.7 Based on randomised controlled trial (RCT) evidence, the 
European Association of Urology guidelines for the management of PE recommend on-demand topical 
lidocaine±prilocaine cream.8 Systematic reviews that have presented a meta-analysis have either not been able to 
pool data across all RCTs due to missing data,9 or have pooled outcome measures reported as arithmetic or 
geometric means together using a standardised mean difference.10 
The aim of this study was to systematically review the evidence for topical anaesthetics in the management of 
PE, by summarising evidence from randomised controlled trials (RCTs) and to undertake a meta-analysis across 
the current evidence base. 
Methods 
The review was undertaken in accordance with the general principles recommended in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.11 
Searches 
The following databases were searched from inception to 5 August 2014 for published and unpublished 
research evidence: MEDLINE; Embase; Cumulative Index to Nursing and Allied Health Literature (CINAHL); 
The Cochrane Library including the Cochrane Systematic Reviews Database (CDSR), Cochrane Controlled 
Trials Register (CCRT), Database of Abstracts of Reviews of Effects (DARE) and the Health Technology 
Assessment (HTA) database; ISI Web of Science (WoS), including Science Citation Index; and the Conference 
Proceedings Citation Index-Science. Full search terms are reported elsewhere.12 The USA Food and Drug 
Administration (FDA) website and the European Medicines Agency (EMA) website were also searched. 
Existing systematic reviews were also checked for eligible studies. All citations were imported into Reference 
Manager Software (version 12, Thomson ResearchSoft, Carlsbad, California) and any duplicates deleted. 
Eligible studies 
Randomised control trials recruiting adult men with PE were included. RCTs that evaluated Severance Secret 
cream (SS-cream ± a topical plant-based preparation comprising extracts of nine plants) were excluded as this 
agent is available for use only in one country (Korea).13 RCTs that evaluated other topical anaesthetic agents 
were eligible for inclusion. Randomised cross-over design studies were excluded to avoid double counting of 
participants in the meta-analysis. Theses and dissertations were not included. Non-English publications were 
included where sufficient data could be extracted from an English-language abstract or tables. 
Outcomes 
The primary outcome was intra-vaginal ejaculatory latency time (IELT). Other outcomes included sexual 
satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life, treatment 
acceptability and adverse events. 
Data extraction 
One reviewer performed data extraction of each included study. All numerical data were then checked by a 
second reviewer. 
Methodological quality of studies 
Methodological quality of RCTs was assessed using the Cochrane Collaboration risk of bias assessment 
criteria.14 :HFODVVLILHG5&7VDVEHLQJDWRYHUDOOµORZ¶ULVNRIELDVLIWKH\ZHUHUDWHGDVVXFKIRUDOOWKUHHRIWKH
following key domains ± (i) allocation concealment; (ii) blinding of outcome assessment; and (iii) completeness 
RIRXWFRPHGDWDDWWULWLRQ:HFODVVLILHG5&7VDVEHLQJDWRYHUDOOµKLJK¶ULVNRIELDVLIWKH\ZHUHUDWHGDV
such for any of these domains. 
Data synthesis 
Where possible, between-group differences for direct comparisons (e.g. selective serotonin re-uptake 
inhibitors (SSRI) vs placebo) were pooled across trials in a pairwise meta-analysis using Cochrane RevMan 
software (version 5.2) (RevMan 2012).15 Continuous outcomes reported as arithmetic and geometric means 
were analysed separately as the mean difference (MD). Where standard deviations or standard errors were not 
presented in the trial report, these were estimated from the range (where reported) using the method described 
by Hozo et al.16 For pooled comparisons where there was little apparent clinical heterogeneity and the I2 value 
(I2 statistic 17) was 40% or less, a fixed-effect model was applied. Random-effects models were applied where 
the I2 value was >40%. Between-group effect estimates were considered significant at P < 0.05. Where more 
than five RCT comparisons were available, publication bias was assessed by visual inspection of funnel plots. 
Results 
Search results 
The searches identified 2331 citations (as part of a wider project assessing a variety of treatments for PE).12 
Of these, 2319 citations were excluded as titles/abstracts. Twelve full-text articles were obtained as potentially 
relevant. The study selection process is fully detailed in the PRISMA flow diagram in Fig. 1. A total of nine 
RCTs that evaluated a topical anaesthetic agent against a comparator (placebo or another agent) were identified. 
Details of the included RCTs, the comparator(s), outcomes assessed and the risk of bias assessment are 
detailed in Table 1. 
Risk of bias assessment of RCTs 
The majority of RCTs were considered to be at an overall unclear risk of bias mainly due to lack of reporting 
of information to inform the risk of bias assessment. Only one RCT reported that a random sequence generation 
method,18 and only one reported that treatment allocation was concealed.19 One RCT prescribed either an oral or 
a topical treatment to treatment groups and as such, participants and caregivers would not have been blinded.20 
One RCT was described as being single-blind.18 Both these RCTs were considered to be at high risk of 
performance bias. In one RCT, numbers withdrawing were imbalanced across groups [placebo 44%, Eutectic 
Mixture of Local Anaesthetics (EMLA), 28%] and data were analysed per-protocol (withdrawals exclude).19 
One reported that 30% of participants withdrew overall but did not reported how many withdrew by treatment 
group.21 Both RCTs were considered to be at an overall high risk due to attrition bias. A summary of the risk of 
bias assessment for each included RCT is presented in Fig. 2. 
Characteristics of RCTs 
Randomised control trial details of the treatments, efficacy and safety outcomes, and the risk of bias 
assessment are presented in Table 1. Where reported, the definition of PE was varied and was defined according 
to: DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria,19,20,22,23 ISSM (International 
Society for Sexual Medicine) criteria,24 an IELT of 2 min or less,18 1 min or less,25 or was not reported.26 The 
majority of RCTs recruited samples comprising men with lifelong PE and without erectile dysfunction. 
A Eutectic Mixture of Local Anaesthetics cream containing lidocaine and prilocaine was prescribed by four 
RCTs, 19,20,25,26 whereas three RCT prescribed topical eutectic-like mixture for premature ejaculation (TEMPE) 
spray containing lidocaine and prilocaine.22±24 One RCT prescribed a lidocaine gel18 and one a lidocaine spray.21 
Application of topical anaesthetic agents ranged from 5 min22 to 45 min before sexual intercourse.25 One RCT 
compared applications of EMLA 20, 30 and 45 min before sexual intercourse.25 
With the exception of one RCT,21 all RCTs included a placebo group comparison. Other comparators 
included SSRI,18,21 phosphodiesterase-5 (PDE5) inhibitors,18,20 electric stimulation26 and tramadol.18 Treatment 
duraWLRQUDQJHGIURPILYHDSSOLFDWLRQVWRZHHNV7KHPDMRULW\RILQFOXGHG5&7VZHUHRIZHHNV¶GXUDWLRQ
Four RCTs were undertaken in North America or EU countries.21±24 The remainder were undertaken in Brazil,19 
Egypt,18 Tunisia26 and Turkey.20,25 
Outcome data reported by RCTs 
With the exception of the RCT by Atan et al.,20 IELT was assessed by all of the included RCTs (Table 1, Figs 
3,4). Where reported, the assessment method was by stopwatch. The reporting of other efficacy outcomes was 
much more varied, both in the assessment method and the outcome data available (Table 1). Across the majority 
of RCTs, outcome data for adverse event reporting was disparate in terms of limited reporting of types of 
adverse events and patient numbers. 
Data synthesis 
Intra-vaginal ejaculatory latency time as a mean outcome with a variance estimate was available for all but 
two RCTs that reported IELT outcomes, but without any variance estimates. Mallat et al.26 reported a P-value 
for IELT of P < 0.001, but it was unclear if this was across or between groups, or whether this was for end of 
study values or change from baseline. Steggall et al.21 reported a P-value for median IELT change from baseline 
of P = 0.038 for lidocaine spray and P < 0.0005 for paroxetine. 
IELT: topical anaesthetics vs placebo 
Meta-analysis of mean IELT (min) following an application of EMLA cream d 20 min pre-intercourse, based 
on two RCTs (n = 49), displayed low heterogeneity (I2 = 0%). The pooled mean difference (MD) in IELT was 
6.44, significantly favouring EMLA [MD (fixed effect) 95% confidence interval (CI), 6.01 to 6.87; P < 
0.00001]. The between-group difference in mean IELT (min) based on one RCT (n = 54), was 3.10, 
significantly favouring TEMPE spray [MD (fixed effect) 95% CI, 1.33 to 5.27; P = 0.001]. Meta-analysis of 
geometric mean IELT (min) based on two RCT study group comparisons (n = 49), displayed low heterogeneity 
(I2 = 0%). The pooled MD in IELT was 2.10 significantly favouring TEMPE spray [MD (fixed effect) 95% CI, 
1.27 to 2.93; P < 0.00001]. The between-group difference in end of study values based on one RCT (n = 57) 
was 3.29 min (95% CI 2.60 to 3.98; P < 0.00001), in favour of lidocaine gel. The forest plot for these analyses is 
presented in Fig. 3. 
Other outcomes: topical anaesthetics vs placebo 
Three RCTs did not report any effectiveness outcomes other than IELT (Atikeler et al. 2002;25 Atan et al. 
2006;20 Steggall et al. 200821). A statistically significant between-group difference in sexual satisfaction in 
favour of EMLA cream after 2 months was reported by Busato and Galindo (2004).19 There appeared to be no 
difference between EMLA cream and placebo on the International Index of Erectile Dysfunction (IIEF) number 
of coitus per week and sexual satisfaction values reported by one RCT (Mallat et al. 2012).26 The between-
group differences on the Index of Ejaculatory Control and Sexual Quality of Life (SQoL) for both men and 
women were reported as being not statistically significant at 4 weeks in one RCT comparing TEMPE with 
placebo (Dinsmore et al. 200723). However, two RCTs reported that the TEMPE spray was significantly more 
effective than placebo at 12 weeks on the Index of Premature Ejaculation (IPE) measures including ejaculatory 
control, sexual satisfaction and distress, and on the Premature Ejaculation Profile (PEP) (Dinsmore and Wyllie 
2009;27Carson and Wyllie 2010;22). One RCT18 reported that end of study mean improvement in sexual 
satisfaction was significantly higher with lidocaine gel than that of the placebo group (P < 0.05). 
IELT: topical anaesthetics vs oral agent 
One RCT18 compared a lidocaine gel with tramadol, sildenafil and paroxetine, in addition to comparison with 
a placebo. The between-group difference in end of study values were 0.83 min (95% CI 0.05±1.16; P = 0.04) in 
favour of lidocaine gel compared with sildenafil and 1.53 min (95% CI 0.76±2.30; P = 0.0001) in favour of 
lidocaine gel compared with paroxetine. Tramadol was significantly more effective than lidocaine gel (1.21min, 
35 95% CI 0.23±2.19; P = 0.02).. The forest plot for these analyses is presented in Fig. 4. The same RCT 
reported that end of study mean improvement in sexual satisfaction was significantly higher with both tramadol 
and sildenafil when compared with lidocaine gel (P < 0.05). 
Adverse events: topical anaesthetics vs placebo 
Meta-analysis of patient numbers experiencing adverse events following treatment with topical anaesthetics 
displayed low heterogeneity (I2 = 0%). The between-group difference in EMLA cream applied for t
compared with placebo was not statistically significant [RR 9.06 (fixed effect) 95% CI 0.55±150.06; P = 0.12]. 
However, Atikeler et al. (2002)25 reported that EMLA cream caused 6/10 men in the 30 min application group 
and 10/10 men in the 45 min application group to report erection loss or numbness. 
The pooled relative risk (RR) across three trials comparing TEMPE spray with placebo (593 participants) 
was 3.25 [RR (fixed effect) 95% CI 1.50±7.02; P = 0.003] in favour of placebo (lower risk). The forest plot for 
this analysis is presented in Fig. 5. 
Adverse events were not reported for one RCT (Steggall et al. 200821). Where reported, adverse events 
associated with topical anaesthetics included: erectile dysfunction/loss of erection, loss of sensitivity/numbness 
(men and women) and irritation/burning (men and women). One RCT reported 22/30 (73%) participants 
receiving lidocaine gel reported penile anaesthesia in the lidocaine gel group, compared with none receiving 
sildenafil, paroxetine, tramadol or placebo. Greater sleep disturbance, dry mouth, nausea, dizziness, fatigue, 
vomiting, sweating and headache were reported with tramadol, sildenafil and paroxetine. All side-effects were 
reported as being tolerable.18 
Discussion 
The aim of this study was to systematically review the evidence for topical anaesthetics in the treatment of 
PE and to pool evidence from RCTs for the effects of topical anaesthetics on IELT in a mean difference meta-
analysis. The present systematic review is an extension to our HTA (Health Technology Assessment) short 
report on treatments for premature ejaculation.12 In the HTA short report, searches were run to August 2013 and 
rapid review methods were employed by extracting RCT outcome data reported in existing reviews without 
obtaining the RCT publication in full. Only RCTs not already captured by existing reviews were obtained in full 
for data extraction and assessment of methodological quality. The present review has run searches to August 
2014, has applied full systematic review methods, obtaining in full all RTCs evaluating topical anaesthetics 
identified for inclusion for data extraction and assessment of methodological quality. Two further RCTs 
published subsequent to the HTA short report searches have been identified,18,26 one of which compares topical 
anaesthetics with oral agents.18 
The pooled evidence across two RCTs19,25 including 49 participants suggests that EMLA cream is effective in 
significantly increasing IELT in men with PE when compared with placebo [mean difference 6.44 (95% CI 
6.01±6.87) min, P < 0.00001]. Evidence from one RCT23 (54 participants) suggests that TEMPE spray is 
effective in significantly increasing IELT in men with PE when compared with placebo [mean difference 3.10 
(95% CI 1.05±5.15) min, P = 0.003]. Evidence from one RCT18 suggests that lidocaine gel is significantly more 
effective than placebo [57 participants, mean difference 3.29 (95% CI 2.60±3.98) min, P < 0.00001], that 
lidocaine gel significantly more effective than sildenafil (60 participants, 0.83 min, P = 0.04), and that lidocaine 
gel is also significantly more effective than paroxetine (58 participants, 1.53 min, P = 0.0001). However, 
evidence from the same trial also suggests that tramadol is significantly more effective than lidocaine gel (59 
participants, 1.21 min, P = 0.02). 
Evidence from one RCT19 comparing EMLA cream with placebo suggests significant improvements in 
sexual satisfaction with EMLA, while another RCT suggests no significant difference.26 Conflicting evidence 
also exists for TEMPE spray. Evidence from two RCTs22,27 comparing TEMPE with placebo suggest significant 
improvements in both sexual satisfaction and ejaculatory control with TEMPE, while anotherRCT suggests no 
significant difference in sexual quality of life or ejaculatory control.23 One RCT comparing lidocaine gel with 
placebo suggests significant improvements in sexual satisfaction with lidocaine gel.18 However, diverse 
assessment methods are evident across the RCTs reporting these outcomes. 
Pooled evidence across three RCTs22±24 (49 participants) suggests there are significantly more adverse events 
associated with TEMPE compared with placebo or EMLA. These include loss of sensitivity/numbness and 
irritation/burning for both men and women. Erectile dysfunction and loss of erection are also reported with 
EMLA, but appear to be related to treatment applications t 20 min pre-intercourse. Greater sleep disturbance, 
dry mouth, nausea, dizziness, fatigue, vomiting, sweating and headache are reported with tramadol, sildenafil 
and paroxetine use. 
Two of the RCTs19,21 reported high rates of attrition and two18,20 were considered at high risk of performance 
bias as they were not of a double-blind. The majority of RCTs were considered at overall unclear risk of bias 
mainly due to lack of reporting of information to inform the risk of bias assessment. The findings should 
therefore be interpreted with caution given the methodological quality of the available evidence. Key aspects of 
best practice in RCT design to minimise bias include a robust randomisation method, concealment of treatment 
group allocation, and, where possible, blinding of participants and trial personnel, and blinded outcome 
assessment; all of which should be clearly stated in the RCT report.28 In addition, patient acceptability of this 
treatment modality (topical application) for PE has not been evaluated in the current evidence base. 
Although our database search strategy was comprehensive, the possibility of a publication bias cannot be 
discounted. Insufficient numbers of RCT comparisons were available for a formal assessment of publication 
bias using funnel plots to be undertaken. Nonetheless, although the majority of RCTs identified for inclusion 
were of unclear methodological quality, it could be considered unlikely that any additional, unpublished data for 
the effects of topical anaesthetics would contribute significantly to the overall findings of this review. 
The results observed by this review for the effectiveness of topical anaesthetics in the treatment of PE are 
comparable with other reviews.9,10 However, where meta-analyses have previously been undertaken, IELT data 
reported as arithmetic means have been pooled with geometric means using a standardised mean difference.10 
This review has pooled data across RCTs, where appropriate, in a meta-analysis using a mean difference to 
summarise IELT outcomes, analysing separately RCTs reporting geometric means (log-transformed). Log-
transformed and untransformed data are not recommended to be pooled together in a meta-analysis.29 
Furthermore, this review has been able to include evidence for topical anaesthetics compared with oral agents 
prescribed off-label for the treatment of PE. 
The RCTs evaluating topical anaesthetics identified for inclusion in this review evaluated treatments over 4±
12 weeks. None reported a long-term follow up on efficacy and safety outcomes or treatment persistence. 
Systemic adverse events were more prevalent with oral treatments, which may make topical anaesthetics more 
acceptable. Likewise, the rapid action of topical anaesthetics compared with planning to take oral medication in 
advance might also be more acceptable. Conversely, the inconvenience of washing and transfer of the agent to 
the partner might be limiting factors to acceptability. Participant preference was not an outcome assessed by any 
RCT. However, more important is a requirement for clearer evaluations of the relationship between treatment-
related increases in IELT, ejaculatory control and sexual satisfaction associated with topical anaesthetics. One 
RCT suggests that tramadol is more effective than topical anaesthetics at increasing IELT in men with PE; 
however, the long-term use of tramadol for the treatment of PE, in terms of a safety profile including addiction 
potential, is unclear from the current evidence base. 
The European Association of Urology 2014 Guidelines on male sexual dysfunction recommend that 
SKDUPDFRORJLFDOWUHDWPHQWRSWLRQVLQFOXGHµRQGHPDQG¶GDSR[HWLQHGDLO\XVHRIDORQJHr-acting SSRI (off-label 
use), daily use of clomipramine (off-ODEHOXVHµRQGHPDQG¶WRSLFDOOLGRFDLQH±prilocaine cream (off-label use) 
DQGµRQGHPDQG¶WUDPDGRORII-label use).8 Given that topical anaesthetics have been extensively evaluated 
against placebo for the treatment of PE in the current evidence base, with limited head-to-head comparisons 
between topical anaesthetics and other treatments (paroxetine, sildenafil and tramadol), further direct 
comparisons between topical anaesthetics and other SSRIs, including dapoxetine and other PDE5 inhibitors, 
should now be investigated. While the observed increases in IELT were statistically significant in favour of 
topical anaesthetics for most comparators, it is difficult to quantify how acceptable and meaningful these 
changes are for men with PE, without being able to evaluate the relationship between IELT, ejaculation control 
and sexual satisfaction from the current RCT evidence-base for topical anaesthetics. The trade-off between 
IELT and other effectiveness outcomes versus adverse effects should also be further evaluated as should 
treatment acceptability and persistence. 
Conclusion 
Topical anaesthetics appear more effective than placebo, paroxetine and sildenafil at increasing IELT in men 
with PE. However, these findings should be interpreted with caution given the limited methodological quality of 
the available evidence. 
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Fig. 1. Study selection process. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram. 
Fig. 2. Risk of bias assessment summary by randomised controlled trial (RCT). 
Fig. 3. Eutectic mixture of local anaesthetics (EMLA) cream, topical eutectic-like mixture for premature 
ejaculation (TEMPE) spray or lidocaine gel vs placebo: forest plot of intra-vaginal ejaculatory latency time 
(IELT) outcomes. 
Fig. 4. Lidocaine gel vs sildenafil, paroxetine or tramadol: forest plot of intra-vaginal ejaculatory latency time 
(IELT) outcomes. 
Fig. 5. Topical anaesthetics vs placebo: forest plot of adverse events. 
  
Table 1. Randomised control trial (RCT) characteristics, efficacy and safety outcomes and 
risk of bias assessment 
AE, adverse events; DSM, Diagnostic and Statistical Manual of Mental Disorders; ED, erectile 
dysfunction; IELT, intra-vaginal ejaculatory latency time; IIEF, International Index of Erectile 
Function; EMLA, eutectic mixture of local anaesthetics; IPE, Index of Premature Ejaculation; ISSM, 
International Society for Sexual Medicine; NR, not reported; PC, pre-coitus; PE, premature 
ejaculation; PEP, Premature Ejaculation Profile; sQoL, sexual quality of life; TEMPE, topical 
eutectic-like mixture for premature ejaculation 
RCT (country) 
Duration 
PE definition, 
lifelong/acquired 
PE, erectile 
dysfunction 
Treatment, 
comparator, 
numbers analysed/ 
randomised (%), 
when taken 
Efficacy outcomes 
and results 
Adverse events Risk of bias 
assessment 
Atan et al. 
2006 20 
(Turkey) 8 
weeks 
DSM-IV Lifelong 
and acquired ED, 
IIEF ED <21 
excluded 
± Topical EMLA 
applied 15 min PC, 
n=22 
± Sildenafil 50 mg 
45 min PC, n=20 
± Sildenafil 50 mg 
45 min PC + topical 
EMLA applied 15 
min PC, n=15 
± Oral placebo, 
n=20  
n analysed NR 
assume 100% 
IELT not assessed  
 
µ,PSURYHPHQW¶RU
µFXUH¶(0/$
Sildenafil, 55% (P > 
0.05); Sildenafil + 
EMLA, 86%; 
Placebo, 40%. (Not 
reported if P-value 
across or between 
groups) 
Only patients 
receiving sildenafil 
experienced side 
effects: headache, 
26%; flushing, 
26% 
Unclear risk ± no 
statement on 
allocation 
concealment, 
blinded outcome 
assessment or 
withdrawals 
Atikeler et al. 
200225 
(Turkey) t 5 
applications 
IELT <1 min 
Lifelong ED, NR 
± EMLA 2.5 g 
applied with 
condom: 
± 20 min PC, n=10 
± 30 min PC, n=10 
± 45 min PC, n=10 
± Placebo cream 
applied with 
condom 20 min PC, 
n=10 
 n analysed NR 
assume 100% 
IELT (stopwatch): 
see Fig. 3. 
 
No other outcomes 
reported 
n/N (%) 
experiencing AEs: 
 
EMLA 20 min, 
0/10 (0%); 
placebo, 0/10 (0%) 
 
Erection loss or 
numbness: 30 min 
group, 6/10; 45 
min group, 10/10 
Unclear risk - no 
statement on 
allocation 
concealment or 
blinded outcome 
assessment 
Busato and 
Galindon200419 
(Brazil) 4±8 
weeks 
DSM-IV Lifelong 
and acquired ED 
excluded 
± EMLA 2.5 g with 
condom 10±20 min 
PC, 16/24 (67%) 
± Placebo cream 
with condom 20 min 
PC, 13/18 (72%) 
IELT (stopwatch): 
see Fig. 3. 
 
Sexual satisfaction: 
 
EMLA, 8.7; Placebo, 
4; P = 0.001. 
 
Q1UHSRUWLQJµJUHDW¶
RUµH[FHOOHQW¶
satisfaction: EMLA, 
6/16; 5/16; Placebo, 
3/13; 0/13 
n/N (%) 
experiencing AEs: 
 
EMLA, 5/16 
(31.3%); placebo, 
0/13 (0%) 
 
EMLA-associated 
AEs: 
Men, 2/29 retarded 
ejaculation, 2/29 
loss of sensitivity, 
2/29 penile 
irritation;  
Women 1/29 
decreased 
High risk ± 
numbers 
withdrawing 
imbalanced across 
groups ± placebo 
44%, EMLA 28%; 
analysed per-
protocol 
RCT (country) 
Duration 
PE definition, 
lifelong/acquired 
PE, erectile 
dysfunction 
Treatment, 
comparator, 
numbers analysed/ 
randomised (%), 
when taken 
Efficacy outcomes 
and results 
Adverse events Risk of bias 
assessment 
sensitivity 
Carson and 
Wyllie 201022 
(USA, Canada 
and Poland) 12 
weeks 
DSM-IV and 
ISSM Lifelong 
and acquired ED 
excluded 
± TEMPE spray 3 
actuations (each 7.5 
mg lidocaine, 2.5 
mg prilocaine) 5 
min PC, 167/167 
(100%) 
± Placebo spray 3 
actuations, 82/82 
(100%) 
IELT (stopwatch): 
see Fig. 3. 
 
Ejaculatory control 
(IPE): TEMPE, 11.6; 
placebo, 6.5  
 
Sexual satisfaction 
(IPE): TEMPE, 13.4; 
placebo, 8.6  
 
Distress (IPE): 
TEMPE, 6.1; 
placebo, 3.7  
 
PEP t 1 point 
improvement: P < 
0.0001 (unclear if 
between groups or 
baseline) 
n/N (%) 
experiencing AEs: 
 
TEMPE, 17/167 
(10%); placebo, 
1/82 (<1%) 
Unclear risk ± no 
statement on 
allocation 
concealment or 
blinded outcome 
assessment 
Dinsmore and 
Wyllie 200723 
(UK and The 
Netherlands) 4 
weeks 
DSM-IV Lifelong 
ED excluded 
± TEMPE 3 
actuations (each 7.5 
mg lidocaine, 2.5 
mg prilocaine) 15 
min PC, 20/27 
(74%) 
± Placebo spray 3 
actuations, 23/28 
(82%) 
IELT (stopwatch): 
see Fig. 3. 
 
Ejaculatory control 
(IEC) change: 
TEMPE, 6.7; 
placebo, 3.0; P = 
0.12  
 
SQoL change: 
TEMPE, men 7.0, 
women 3.3. Placebo, 
men 5.5, women 1.8. 
P-value men, 0.48; 
women, 0.56 
n/N (%) 
experiencing AEs: 
TEMPE, 6/26 
(23%); placebo, 
4/28 (14%) 
 
TEMPE: 
hypoaesthesia, 
3/26; erectile 
dysfunction, 1/26.  
Women: mild 
burning 1/26 
Unclear risk ± no 
statement on 
allocation 
concealment or 
blinded outcome 
assessment 
Dinsmore  and 
Wyllie 200924 
(31 sites across 
Europe) 12 
weeks 
ISSM Lifelong 
and acquired ED 
excluded 
± TEMPE 3 
actuations (each 7.5 
mg lidocaine, 2.5 
mg prilocaine) 5 
min PC, 191/200 
(96%) 
± Placebo spray 3 
actuations, 99/100 
(99%) 
IELT (stopwatch): 
see Fig. 3. 
 
Ejaculatory control 
(IPE):  
TEMPE, 14.3; 
placebo, 7.4  
 
Sexual satisfaction 
(IPE): TEMPE, 14.8; 
placebo, 9.1  
 
Distress (IPE): 
TEMPE, 7.1; 
placebo, 4.5  
 
PEP t 1 point 
improvement: P < 
0.001 (unclear if 
n/N (%) 
experiencing AEs: 
TEMPE, 18/191 
(9%); placebo 3/99 
(3%) 
 
Genital burning, 
erythema and 
hypoaestheia 
(male) and 
vulvovaginal 
burning discomfort 
(female) reported 
with TEMPE, but 
not placebo 
Unclear risk ± no 
statement on 
allocation 
concealment or 
blinded outcome 
assessment 
RCT (country) 
Duration 
PE definition, 
lifelong/acquired 
PE, erectile 
dysfunction 
Treatment, 
comparator, 
numbers analysed/ 
randomised (%), 
when taken 
Efficacy outcomes 
and results 
Adverse events Risk of bias 
assessment 
between groups or 
baseline) 
Gameel et al. 
201318 (Egypt) 
4 weeks 
IELT of <2 min in 
>75% of 
episodes. All had 
PE for >1 year 
ED, excluded 
± Lidocaine gel 15 
min PC + oral 
multivitamin 1±4 h 
PC, 30/30 (100%) 
± Tramadol 50 mg 2 
h PC + inert 
lubricating gel 15 
min PC, 29/30 
(97%) 
± Sildenafil 50 mg 1 
h PC + inert 
lubricating gel 15 
min PC, 30/30 
(100%) 
± Paroxetine 20 mg 
4 h PC + inert 
lubricating gel 15 
min PC, 28/30 
(93%) 
± Placebo (oral 
multivitamin 1±4 h 
PC + inert 
lubricating gel 15 
min PC), 27/30 
(90%) 
IELT (stopwatch): 
see Fig. 3 and Fig. 
4.Sexual satisfaction 
(0 to 5 point scale: 
end of study mean 
improvement in all 
active-treatment 
groups was 
significantly higher 
than in the placebo 
group (P < 0.05). 
Tramadol and 
sildenafil 
significantly greater 
than lidocaine gel (P 
< 0.05) 
22/30 (73%) 
reported penile 
anaesthesia in 
lidocaine gel group 
(none in other 
groups). Greater 
sleep disturbance, 
dry mouth, nausea, 
dizziness, fatigue, 
vomiting, sweating 
and headache were 
reported with 
tramadol, sildenafil 
and paroxetine. All 
side-effects were 
reported as being 
tolerable. 
Unclear risk ± 
allocation method 
and blinded 
outcome 
assessment not 
reported 
Mallat et al. 
2012 26 
(Tunisia) 12 
weeks 
PE definition, NR 
Lifelong/acquired, 
NR ED, NR 
± EMLA applied 1 h 
PC, n=30 
± Electric 
stimulation ± not 
described, n=30 
± Placebo ± not 
described, n=30  
n analysed NR, 
assume 100% 
IELT (method NR): 
EMLA increased to 
3.35 min; ES 
increased to 4.05; 
placebo to 0.57, P < 
0.001 but unclear if 
change from baseline 
or across groups. No 
variance estimates 
reported. Mean 
weekly intercourse 
and IIEF intercourse 
satisfaction P < 0.05 
but unclear if change 
from baseline or 
across groups 
More adverse 
events associated 
with EMLA (not 
described), but no 
withdrawals due to 
AEs 
Unclear risk ± no 
statement on 
allocation 
concealment, 
blinded outcome 
assessment or 
withdrawals 
Steggall et al. 
200821(UK) 4 
weeks 
DSM IV 
diagnosis plus 
IELT d 3 min. 
Lifelong and 
acquired ED, NR 
± Lidocaine 3±8 
sprays applied 10 
min PC, n=17 
± Paroxetine 20 mg 
per day, n=27  
 
Total analysed, 
44/60 (73.3%)  
n randomised by 
group NR 
IELT (stopwatch) 
week 4: 
Lidocaine ± mean, 
3.03 min; median, 
2.75 (P = 0.038, 
assume for change); 
geometric mean, 
3.68 Paroxetine ± 
mean, 4.71 min; 
median, 3.00 (P < 
0.0005, assume for 
change); geometric 
Adverse events NR High risk ± 30% 
withdrew overall 
and not reported 
how many 
withdrew by group. 
RCT (country) 
Duration 
PE definition, 
lifelong/acquired 
PE, erectile 
dysfunction 
Treatment, 
comparator, 
numbers analysed/ 
randomised (%), 
when taken 
Efficacy outcomes 
and results 
Adverse events Risk of bias 
assessment 
mean, 3.68  
 
No variance 
estimates reported 
 
  
Figure 1. Study Selection Process - Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) Flow Diagram. 
 
 
Records identified 
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searching 
(n=2,331) 
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Additional records 
identified through 
other sources 
(n=0) 
Records screened ʹ  
title and/or abstract 
(n=2,331) 
Records excluded at 
title/abstract stage: 
Not relevant (n=2,319) 
Full-text articles assessed 
for eligibility 
(n=12) 
Full-text articles excluded, with 
reasons (n=3): 
Review of topical agents (n=2) 
Crossover topical agent trials (n=1) 
9 RCTs included in the evidence synthesis 
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Figure 2. Risk of bias assessment summary by RCT 
 
?, unclear risk of bias; +, low risk of bias, -, high risk of bias 
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Figure 3. EMLA cream, TEMPE spray or lidocaine gel vs. placebo - forest plot of IELT 
outcomes 
 
Figure 4. Lidocaine gel vs. sildenafil, paroxetine or tramadol - forest plot of IELT outcomes 
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Figure 5. Topical anaesthetics vs. placebo - forest plot of adverse events 
 
 
